AMR poses a critical threat to global public health undermining decades of progress made in the field of modern medicine
At 24 months, data from the Phase 1 exPDite trial continue to show a favorable safety profile in all 12 participants in the trial’s high and low dose cohorts
The mobile unit "Breast Health Express" brings advanced medical technology directly to communities in need
These clinical studies support the interchangeability of adalimumab-fkjp at low-concentration with high-concentration adalimumab and ustekinumab biosimilarity
Doses will be ready to ship to applicable European Union (EU) member states as soon as possible upon European Commission (EC) authorization
New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids
Stable profits, low leverage to keep credit profiles comfortable
Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma
This approval is backed by a decade of proven safety and efficacy data of Ocrevus® IV, with over 350,000 people treated globally
Subscribe To Our Newsletter & Stay Updated
